Key result
Encephalomyocarditis virus causes fatal myocarditis in primates and shows ~47% seroprevalence in high-risk humans.
Answers are grounded in this paper and cite their sources.
Encephalomyocarditis virus is an underrecognized rodent-borne Cardiovirus that causes fatal acute myocarditis in non-human primates and widespread subclinical or febrile zoonotic exposure in humans, requiring stricter rodent biosecurity and diagnostic surveillance.
Many emerging zoonotic viruses pose major risks to animal and human health, with most recent epidemics of viral origin. This review focuses on encephalomyocarditis virus (EMCV), a member of the Picornaviridae family and the Cardiovirus genus with significant but largely underrecognized zoonotic potential. While EMCV has not yet caused major public health crises, its broad host range and rodent reservoir suggest a wider ecological impact. It is typically detected only during high-fatality outbreaks, particularly in domestic animals and non-human primates (NHPs), which are among the most vulnerable hosts. Multiple fatal outbreaks in captive and semi-captive NHPs have been documented. Human infections appear rare, yet the prevalence of antibodies suggests widespread exposure. EMCV remains largely absent from diagnostic panels and its epidemiology is poorly understood. We argue that EMCV warrants much closer attention due to its ability to cause severe disease in NHPs and its potential risk to humans. This review synthesizes current knowledge on the biology, epidemiology, pathogenicity, diagnosis, and prevention of EMCV in primates.
No takes yet. Share an insight, caveat, or question.
Amona et al. (2026) conducted a review in Encephalomyocarditis virus (EMCV) infection and associated acute myocarditis. Encephalomyocarditis virus (EMCV) exposure was evaluated on Acute myocarditis, encephalitis, and sudden death in non-human primates; seroprevalence and febrile illness in humans. Encephalomyocarditis virus causes high-fatality acute myocarditis outbreaks in captive non-human primates and shows up to 47% seroprevalence in high-risk human groups.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: